Heart Closure Devices Market Size & Share 2025 – 2034

Heart Closure Devices Market Size

The global heart closure devices market size was valued at USD 4 billion in 2024 and is expected to exhibit growth at a CAGR of 15.9% from 2025 to 2034 period. The significant market growth can be explained by a number of factors, such as the rise in the incidence of cardiovascular diseases, increased demand for non-invasive procedures, and positive reimbursement policies.

Every year, millions of people succumb to cardiovascular diseases (CVDs), which, as a disease category, remains the most important on a global scale. The data provided by the World Health Organization (WHO) further indicates that CVDs are responsible for nearly 17.9 million deaths of people every year. As the population ages and lifestyle-related risk factors such as obesity, high blood pressure, diabetes, and a sedentary lifestyle keep increasing, so will the numbers. Such alterations have resulted in more demand for cutting-edge non-invasive alternatives such as heart closure devices, which treat structural heart defects for a wide range of patients from all demographic groups.

Additionally, with the advent of heart closure devices, which are less intrusive, patients do not need to undergo open heart surgery anymore. Because consumers do not want to undergo open-heart surgery, these devices have become popular. They are also known to be less invasive. Cutting-edge non-invasive alternatives, such as heart closure devices, which treat structural heart defects for patients from all demographics across the globe, are in tremendous demand.
 

Moreover, heart closure devices are used in the surgical closure of congenital heart problems, including holes in the heart, specifically ventricular and atrial septal defects. During the birth of the baby, these defects form as abnormal openings which link the chambers of the heart, thus allowing the blood to flow in undesired directions.
 

Heart Closure Devices Market Trends

The market is expanding further due to technology improvement, which further fosters development of safer, more efficient, and less invasive treatment options for patients suffering from structural heart diseases.
 

• Biocompatible heart closure devices have been developed due to changes in the biomaterials used, thereby promoting better patient outcomes since there is a lowered risk of reverse adverse reactions. Modern devices now utilize materials that minimize blood clot formation and device-related infections.
   
• For instance, bioresorbable materials are ideal for pediatric cases where long-term device implantation is not ideal because these materials dissolve naturally with time. This makes it easier to improve the safety profile of heart closure devices, which enhances the patient's and clinician's confidence in using them.
   
• Moreover, developments in imaging technologies, such as three-dimensional echocardiography and intracardiac ultrasound, have revolutionized the visualization of heart defects and their treatment. These state-of-the-art imaging systems capture and display the internal structure of the heart in real-time and in high definition, thereby allowing the operators to minimize the risks associated with the procedure by accurately placing closure devices.
   
• Also, considering the ability to better define the target and the defect, and therefore to treat it more accurately, there is improvement in patient outcomes, which accelerates the incorporation of heart closure devices into the treatment procedures of choice for conditions affecting structural components of the heart.
   

Heart Closure Devices Market Analysis

Based on product, the market is classified into left atrial appendage (LAA) closure devices, atrial septal defect (ASD) closure devices, ventricular septal defect (VSD) closure devices, patent foramen ovale (PFO) closure devices, and other products. The left atrial appendage (LAA) closure devices segment generated the highest revenue of USD 2.2 billion in 2024.
 

• Left atrial appendage closure (LAAC) devices are the leader in the closure treatment market for the heart due to the benefits they offer and cost mitigation assistance that their owners possess. The key benefit of these devices is the mitigation in the risk of stroke.
   
• Furthermore, unlike prolonged anticoagulation with warfarin or with oral anticoagulants, which is accompanied by potential bleeding risks, drug interactions, and the need for monitoring, LAAC devices allow avoiding such measures. This applies more so to people with advanced age, history of major bleeding, or use of other drugs that put them at high risk for bleeding.
   
• In addition, with the increasing demand for less invasive surgeries in more demographics on the rise, the market share for LAAC devices has sustained growth and demand. They are used in place of surgical interventions due to the lower complication rates, the shorter periods of stay in the hospital, and the quicker times of recovery. This brings about a constant increment in the amount of LAAC devices that are used as long as new and better technology is developed and both the healthcare professionals and their patients follow and understand how the devices function.
   

Based on material, the heart closure devices market is classified into nitinol-based devices, stainless steel devices, and other materials. The nitinol-based devices segment is expected to drive business growth and expand at a CAGR of 16%, reaching over USD 9.2 billion by 2034.
 

• Due to the development of superelastic and highly biocompatible nitinol-based devices, these devices now hold the largest market share. They rely on nitinol, which can be melted so that these devices can be tunneled through a delivery catheter for a less invasive procedure. Additionally, owing to its superelasticity, the device is capable of still functioning properly amid the heart's dynamic movements and forces.
   
• Moreover, rapid advancements made in the field of medicine have contributed to an increase in the number of people suffering from cardiovascular diseases which, in turn, has increased the demand for effective heart closure alternatives. These devices are nitinol-based and provide benefits in terms of adapting to mechanical loads for long-term patient safety, which are critical for the performance of the devices.
   
• The market share of nitinol-based heart closure devices should also remain sizeable with the increasing logistical chain efficiency and ongoing fundamental innovations in reliable therapies that healthcare-seeking patients require.
   

Based on mode of delivery, the heart closure devices market is classified into transcatheter delivery and surgical delivery. The transcatheter delivery segment generated the highest revenue of USD 2.5 billion in 2024.
 

• Transcatheter delivery replaces the invasion of open-heart surgery with small incisions or punctures, which means smaller scars, less pain, fewer chances of infection, and shorter recovery periods.
   
• For instance, recovery of patients who undergo transcatheter closure procedures is faster than for patients who have open-heart surgery. In addition, the likelihood of getting complications that are often associated with any surgery, bleeding, infection, and other issues are also lower for transcatheter procedures.
   
• Furthermore, the preference for transcatheter delivery of heart closure devices is increasing because of the benefits it offers over the conventional method. Reduced invasiveness to patients, thereby leading to lower rates of complications, appeals to both the patients and the healthcare sector. So as the transcatheter technology evolves continuously along with the improvement in its awareness, the share of transcatheter heart closure devices in the market will increase substantially.
   

Based on end use, the heart closure devices market is segmented into hospitals, ambulatory surgical centers (ASCs), cardiac catheterization laboratories, and other end users. The hospitals segment dominated the market in 2024 and is anticipated to reach USD 8.6 billion by the end of the forecast period.
 

• Heart closure surgeries, which include atrial septal defect, patent foramen ovale, and ventricular septal defect, are advanced procedures and as such require equally matching facilities, equipment, and specialized medical teams.
   
• Given the serious nature of these surgeries, patients usually prefer hospitals that have such resources and a multidisciplinary medical team that can assist in these procedures on hand.
   
• In addition, heart closure procedures require an advanced skill set of interventional cardiologists, interventional radiologists, and specially trained nurses. Hospitals are equipped with professionals who are well trained in the management of such complicated procedures while ensuring patient safety during the entire process. Not only are there sufficient trained personnel to administer to patients undergoing heart closure procedures, but the level of quality was ensured maximally, leading to positive outcomes for the patients, in turn cementing the dominance of the hospital segment in this industry.
   

North America heart closure devices market accounted for USD 2.7 billion in market revenue in 2024 and is anticipated to grow at a CAGR of 14.3% between the 2025 – 2034 period.
 

• Similarly, there has been a steady increase in Atrial Septal Defect (ASD) and patent foramen ovale (PFO) in the region that might require heart closure interventions. Additionally, North America benefits from early adoption of modern technologies, such as catheter-based procedures, which are minimally invasive, as well as substantial funding for R&D activities that encourage innovations in heart closure devices.
   
• Furthermore, these reimbursement policies make these procedures more affordable, further increasing the market. The U.S. and Canada have the presence of several major market players and are enabling the region to maintain its supremacy in the market owing to the availability of products and technological advances.
   

France heart closure devices market is projected to grow remarkably in the coming years.
 

• The focal point of the French healthcare system is on prevention and detection of cardiovascular diseases, such as congenital heart defects that require heart closure devices, and France being the country has an extensive network of commanding cardiologists and cardiac care centers providing advanced cardiac treatments.
   
• Moreover, government health policies and medical insurance schemes motivate patients diagnosed with structural heart diseases such as ASD and PFO to get treatment. Hence, there is an increase in the demand for heart closure devices in France with a strong background that facilitates the penetration of sophisticated and less invasive heart closure devices.
   

Japan holds a dominant position in the Asia Pacific heart closure devices market.
 

• The government's push for the use of advanced medical technologies has been fostering the timely and effective use of evolutional heart closure devices that include bioresorbable and high-accurate devices.
   
• Moreover, Japan's performance in this space has also been bolstered by the efforts of the administration to improve heart health and availability of cardiovascular devices to the population in general.
   

Heart Closure Devices Market Share

This market has fierce competitors with the main players, manufacturers, and distributors, such as Abbott Laboratories, Boston Scientific Corporation, and Medtronic plc, all competing in the innovative PD market dominated by numerous products. Meanwhile, regional players and foreign entrants from the APAC region are increasing the competition for heart closure devices for local markets at lower prices. Progressive design, increased comfort, precision, and data tracking systems are among the most recent improvements made to the devices that have triggered product continuing development and upgrading.
 

Heart Closure Devices Market Companies

Prominent players operating in the heart closure devices industry include:

• Abbott Laboratories
• AtriCure
• Biosense Webster
• Boston Scientific Corporation
• Cardia
• Heartstitch
• Lepu Medical Technology (Beijing)Co., Ltd.
• LifeTech Scientific Corporation
• Medtronic
• Occlutech
• SentreHEART
• Starway Medical Technology
• W. L. Gore & Associates
   

USPs for key players:

• Abbott leads by implementing design changes to its existing products, such as advanced occluder systems that aid in the efficient correction of structural heart deficits.
   
• Boston Scientific, on the other hand, takes a different approach in providing technologies that are patient-oriented, which entails the use of closure devices that assist in enhancing patient safety and outcomes that reduce recovery time.
   
• W. L. Gore & Associates provides a wide assortment of bridges, grafts, and other devices which make use of advanced polymers specifically designed for the purpose of ensuring accuracy and long-term effectiveness of the devices.
   

Heart Closure Devices Industry News:

• In September 2022, Abbott announced the European launch of Amplatzer Talisman System to close the hole in the heart for people at risk of recurrent stroke. Abbott's Talisman system seals an opening in the heart known as a patent foramen ovale (PFO) to prevent blood clots from passing from the right to the left side of the heart and onto the brain, where they can cause a stroke. Thus, this product launch assisted the company in strengthening its market presence in Europe.
   

The heart closure devices market research report includes in-depth coverage of the industry with estimates and forecasts in terms of revenue in USD Million and volume in Units from 2021 – 2034 for the following segments:

Click here to Buy Section of this Report

Market, By Product

• Atrial septal defect (ASD) closure devices
• Ventricular septal defect (VSD) closure devices
• Patent foramen ovale (PFO) closure devices
• Left atrial appendage (LAA) closure devices
• Other products

Market, By Material

• Nitinol-based devices
• Stainless steel devices
• Other materials

Market, By Mode of Delivery

• Transcatheter delivery
• Surgical delivery

Market, By End Use

• Hospitals
• Ambulatory surgical centers (ASCs)
• Cardiac catheterization laboratories
• Other end users

The above information is provided for the following regions and countries:

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Spain
  • Italy
  • Netherlands
• Asia Pacific
  • China
  • Japan
  • India
  • Australia
  • South Korea
• Latin America
  • Brazil
  • Mexico
  • Argentina
• Middle East and Africa
  • South Africa
  • Saudi Arabia
  • UAE